Radius Health share price soars on abaloparatide-SC Phase III results

Shares in US pharma company Radius Health (Nasdaq: RDUS) surged 15.9% to $59.64 on reports of positive data from its trial of abaloparatide-SC.

The drug showed continued clinical benefit across the 25-month trial period, and gave significant reductions in vertebral, non-vertebral, clinical and major osteoporotic fractures.

Radius previously reported positive results for the Phase III ACTIVE trial, which met its primary endpoint of new vertebral fracture reduction, and secondary endpoints of non-vertebral fracture reduction, and bone density mass increases at spine, femoral neck and total hip.